Lorraine Mooney

AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

Paul R. Gavine, Lorraine Mooney, Elaine Kilgour et al. · Cancer Research · 2012 · 499 citations

Medicine, Oncology, Pharmacology +16

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity

Nicola J. Curtis, Lorraine Mooney, Lorna Hopcroft et al. · Oncotarget · 2017 · 158 citations · Full text

Medicine, Oncology, Pharmacology +13

Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery

Molly A. Taylor, Adina Hughes, Josephine Walton et al. · Journal for ImmunoTherapy of Cancer · 2019 · 102 citations · Full text

Life Sciences, Immunology, Oncology +17

PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity

Larissa S. Carnevalli, Charles Sinclair, Molly A. Taylor et al. · Journal for ImmunoTherapy of Cancer · 2018 · 89 citations · Full text

Medicine, Immunology, Pharmacology +17

Pilot Study of Essential Drug Quality in Two Major Cities in India

Roger Bate, Richard Tren, Lorraine Mooney et al. · PLoS ONE · 2009 · 84 citations · Full text

Pharmacy, Pharmaceutical Analysis, Pharmaceutics +13